MilliporeSigma develops System Service Reliance Plans

Published: 8-Nov-2021
Regulatory

The data sheet is available to download for free now

To ensure optimum equipment uptime and regulatory compliance while mitigating risks, we have developed System Service Reliance Plans; a complete range of services for your systems and equipment. These comprehensive service and support packages allow you to select a coverage level that best fits your needs. The Essential Reliance Plan includes a selection of preventive maintenance and troubleshooting services while the Advanced Reliance Plan provides higher coverage, with faster response time and priority access to remote and on-site support.

All services are performed by our global experts who have intimate knowledge of our equipment, backed by decades of experience.

Download MilliporeSigma's data sheet.

  • Companies:
  • Merck Electronics KGaA
See more

You may also like

Regulatory

Merck announces collaboration with Agilent to fill PAT gap for downstream processing

Read more
Collaboration will help to enable real-time release and Bioprocessing 4.0

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further
  5. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Merck announces collaboration with Agilent to fill PAT gap for downstream processing

Collaboration will help to enable real-time release and Bioprocessing 4.0
Regulatory

Merck licenses foundational CRISPR technology to Cellecta

Cellecta provides RNAi and CRISPR technologies for the discovery and characterisation of novel therapeutic targets and genetic profiling for drug and biomarker discovery and validation
Regulatory

4D pharma, Merck and Pfizer trial combination carcinoma treatment

MRx0518 is currently being evaluated in three clinical trials in patients with cancer
Manufacturing

Big names announced for leading Pharma and Cleanroom conference

The Cleanroom Technology Conference and Manufacturing Chemist Live collaboration will take place on the 10-11 November. Delegate tickets are currently available
Ingredients

Therapeutics: tepotinib for lung cancer

Lung cancer is the most common type of cancer, with an estimated 2 million cases being diagnosed every year and 1.7 million deaths recorded
Packaging

The pharmaceutical supply chain: Are we ready for change?

A tremendous change agent, serialisation data has the power to drive a safer, more efficient pharmaceutical supply chain — for everyone, reports John Bermudez, General Manager, Digital Network Platform, TraceLink
Ingredients

Therapeutics: evobritinib for multiple sclerosis

There is a growing body of evidence suggesting that, as well as regulating normal autoimmunity, B-cells are also involved in immune-mediated diseases, including multiple sclerosis (MS)
Subscribe now